Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions

• Published in: Journal of virology 2020-03, Vol.94 (7)
• Main Authors: Wang, Shixia, Voronin, Yegor, Zhao, Peng, Ishihara, Mayumi, Mehta, Nickita, Porterfield, Mindy, Chen, Yuxin, Bartley, Christopher, Hu, Guangnan, Han, Dong, Wells, Lance, Tiemeyer, Michael, Lu, Shan
• Format: Article
• Language: English
• Subjects: AIDS Vaccines - chemistry; Animals; Antibodies, Monoclonal - immunology; Antibodies, Neutralizing - immunology; CD4-Positive T-Lymphocytes - cytology; CHO Cells; Cricetulus; Epitopes - immunology; Glycosylation; HEK293 Cells; HIV Envelope Protein gp120 - chemistry; HIV-1; Humans; Immunoglobulin G - immunology; Polysaccharides - chemistry; Protein Domains; Recombinant Proteins - chemistry; Vaccines and Antiviral Agents
• ISSN: 0022-538X; 1098-5514
• DOI: 10.1128/JVI.01968-19

Envelope (Env) glycoprotein of human immunodeficiency virus type 1 (HIV-1) is an important target for the development of an HIV vaccine. Extensive glycosylation of Env is an important feature that both protects the virus from antibody responses and serves as a target for some highly potent broadly neutralizing antibodies. Therefore, analysis of glycans on recombinant Env proteins is highly significant. Here, we present glycosylation profiles of recombinant gp120 proteins from four major clades of HIV-1 (A, B, C, and AE), produced either as research-grade material in 293 and CHO cells or as two independent lots of clinical material under good manufacturing practice (GMP) conditions. Almost all potential -linked glycosylation sites were at least partially occupied in all proteins. The occupancy rates were largely consistent among proteins produced under different conditions, although a few sites showed substantial variability even between the two GMP lots. Our data confirmed previous studies in the field, showing an abundance of oligomannose on Env protein, with 40 to 50% of glycans being Man to Man on all four proteins under all production conditions. Overall, the differences in occupancy and glycan forms among different Env subtypes produced under different conditions were less dramatic than anticipated, and antigenicity analysis with a panel of six monoclonal antibodies, including antibodies that recognize glycan forms, showed that all four gp120s maintained their antibody-binding profiles. Such findings have major implications for the final production of a clinical HIV vaccine with Env glycoprotein components. HIV-1 Env protein is a major target for the development of an HIV-1 vaccine. Env is covered with a large number of sugar-based glycan forms; about 50% of the Env molecular weight is composed of glycans. Glycan analysis of recombinant Env is important for understanding its roles in viral pathogenesis and immune responses. The current report presents the first extensive comparison of glycosylation patterns of recombinant gp120 proteins from four major clades of HIV-1 produced in two different cell lines, grown either under laboratory conditions or at 50-liter GMP scale in different lots. Information learned in this study is valuable for the further design and production of HIV-1 Env proteins as the critical components of HIV-1 vaccine formulations.